相似文献
1
Proton pump inhibitors and gastric neoplasia.
Gut. 2006 Sep;55(9):1217-21. doi: 10.1136/gut.2005.090514.
2
Should Helicobacter pylori be eradicated before starting long-term proton pump inhibitors?
Ital J Gastroenterol Hepatol. 1997 Dec;29(6):569-73.
3
Long-term safety and efficacy of omeprazole in gastro-oesophageal reflux disease.
Lancet. 2000 Aug 19;356(9230):610-2. doi: 10.1016/S0140-6736(00)02598-8.
4
Rationale for a Helicobacter pylori Test and Treatment Strategy in Gastroesophageal Reflux Disease.
Gastroenterol Clin North Am. 2015 Sep;44(3):661-6. doi: 10.1016/j.gtc.2015.05.007. Epub 2015 Jun 19.
5
Review article: Helicobacter pylori and gastro-oesophageal reflux disease.
Aliment Pharmacol Ther. 2005 Aug;22 Suppl 1:32-40. doi: 10.1111/j.1365-2036.2005.02607.x.
6
Little necessity of acid inhibition against proton pump inhibitor rebound effects and prior helicobacter pylori eradication therapy in gastric ulcer patients: a randomized prospective study.
Hepatogastroenterology. 2009 May-Jun;56(91-92):624-8.
7
Helicobacter pylori infection and long term proton pump inhibitor therapy.
Gut. 2004 Jan;53(1):5-7. doi: 10.1136/gut.53.1.5.
8
Long-term safety of proton pump inhibitors: risks of gastric neoplasia and infections.
Expert Opin Drug Saf. 2002 May;1(1):29-38. doi: 10.1517/14740338.1.1.29.
9
Problems associated with the clinical use of proton pump inhibitors.
Pharmacol Toxicol. 2001 Dec;89(6):281-6. doi: 10.1034/j.1600-0773.2001.d01-161.x.
10
Gastroesophageal reflux disease.
N Engl J Med. 2009 Feb 12;360(7):729; author reply 729-30.
引用本文的文献
1
Proton pump inhibitors and the risk of gastric cancer: a systematic review, evidence synthesis and life course epidemiology perspective.
BMJ Open Gastroenterol. 2025 Apr 19;12(1):e001719. doi: 10.1136/bmjgast-2024-001719.
2
The influence of , proton pump inhibitor, and obesity on the gastric microbiome in relation to gastric cancer development.
Comput Struct Biotechnol J. 2023 Nov 30;23:186-198. doi: 10.1016/j.csbj.2023.11.053. eCollection 2024 Dec.
3
Use of proton pump inhibitors for the risk of gastric cancer.
Medicine (Baltimore). 2022 Dec 9;101(49):e32228. doi: 10.1097/MD.0000000000032228.
4
Clinicopathological features of gastric cancer after pancreaticoduodenectomy: reporting of three institutional cases and review of the global literature.
Langenbecks Arch Surg. 2022 Sep;407(6):2259-2271. doi: 10.1007/s00423-022-02524-6. Epub 2022 May 6.
5
Pretreatment Levels of Chromogranin A and Neuron-specific Enolase in Patients With Gastroenteropancreatic Neuroendocrine Neoplasia.
In Vivo. 2021 Sep-Oct;35(5):2863-2868. doi: 10.21873/invivo.12574.
6
Autoimmune atrophic gastritis in systemic sclerosis.
BMJ Case Rep. 2021 Aug 13;14(8):e242851. doi: 10.1136/bcr-2021-242851.
7
Proton Pump Inhibitor Use, Hypergastrinemia, and Gastric Carcinoids-What Is the Relationship?
Int J Mol Sci. 2020 Jan 19;21(2):662. doi: 10.3390/ijms21020662.
8
Insights into the biology and treatment strategies of pancreatic neuroendocrine tumors.
Ann Pancreat Cancer. 2019 Jun;2. doi: 10.21037/apc.2019.06.02. Epub 2019 Jun 20.
9
Gastric outlet obstruction secondary to a pedunculated hyperplastic polyp with early malignant changes.
J Taibah Univ Med Sci. 2017 Nov 20;13(3):305-308. doi: 10.1016/j.jtumed.2017.10.004. eCollection 2018 Jun.
10
Adverse Effects of Proton Pump Inhibitors on Platelet Count: A Case Report and Review of the Literature.
Case Rep Gastrointest Med. 2018 Apr 30;2018:4294805. doi: 10.1155/2018/4294805. eCollection 2018.
本文引用的文献
1
Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report.
Gut. 2007 Jun;56(6):772-81. doi: 10.1136/gut.2006.101634. Epub 2006 Dec 14.
2
Persistence and adherence to proton pump inhibitors in daily clinical practice.
Aliment Pharmacol Ther. 2006 Jul 15;24(2):377-85. doi: 10.1111/j.1365-2036.2006.02982.x.
3
Declining incidence of peptic ulcer but not of its complications: a nation-wide study in The Netherlands.
Aliment Pharmacol Ther. 2006 Jun 1;23(11):1587-93. doi: 10.1111/j.1365-2036.2006.02918.x.
4
Changes of gastric mucosal architecture during long-term omeprazole therapy: results of a randomized clinical trial.
Aliment Pharmacol Ther. 2006 Mar 1;23(5):639-47. doi: 10.1111/j.1365-2036.2006.02792.x.
5
The risk of missed gastroesophageal cancer diagnoses in users and nonusers of antisecretory medication.
Gastroenterology. 2005 Oct;129(4):1179-86. doi: 10.1053/j.gastro.2005.07.028.
6
National adherence to evidence-based guidelines for the prescription of nonsteroidal anti-inflammatory drugs.
Gastroenterology. 2005 Oct;129(4):1171-8. doi: 10.1053/j.gastro.2005.08.003.
7
Increasing incidence of Barrett's oesophagus in the general population.
Gut. 2005 Aug;54(8):1062-6. doi: 10.1136/gut.2004.063685. Epub 2005 Apr 27.
8
Empirical use of antisecretory drug therapy delays diagnosis of upper gastrointestinal adenocarcinoma but does not effect outcome.
Aliment Pharmacol Ther. 2004 May 1;19(9):981-8. doi: 10.1111/j.1365-2036.2004.01924.x.
9
10
Underutilization of preventive strategies in patients receiving NSAIDs.
Rheumatology (Oxford). 2003 Nov;42 Suppl 3:iii23-31. doi: 10.1093/rheumatology/keg495.
Zotero 插件